AMLX · Amylyx Pharmaceuticals
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $39.66
Note written ·
Price against the kill line
23.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $39.66, on record since 11 November 2026. The shares are up 41.3% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $39.66, the August 2026 closing peak after the topline data, would show the shares leading the S&P 500 and prove this call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 31 December 2025, filed 3 March 2026
- Revenue, latest quarter ($M)
- 0.0
- Gross margin (%)
- 100.0
- Operating margin (%)
- −18187.7
- Net cash, cash less debt ($M)
- 768
All filed numbers
What Amylyx Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 0.0 | — | — | — |
| first filed | 0.0 | −100.0 | — | — |
| first filed | 0.0 | — | — | — |
| first filed | 0.0 | −100.0 | — | — |
| first filed | 0.4 | −99.6 | 100.0 | −18187.7 |
| Pre-tax income ($M) quarter to 31 December 2025, filed 3 March 2026 | −33.0 |
| Net income ($M) four quarters: −163 | −45.5 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +27.4 |
| Operating cash flow ($M) | −130 |
| Capital spending ($M) | Not available |
| Free cash flow ($M) | Not available |
| Cash and short-term investments ($M) | 768 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 768 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) at 31 December 2025, filed 3 March 2026 | 0.1 |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 754 |
| Market value ($M) | 3,894 |
| Enterprise value, market value plus net debt ($M) no debt reported | 3,126 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 5.2 |
| Free-cash-flow yield (%) | Not available |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 10.3% of shares outstanding sold short, 9.9 days of average trading to cover, +4.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $11.0M |
| 12 monthsfrom | $152K | $17.3M |
The thesis
Amylyx Pharmaceuticals' shares are more likely to lag the S&P 500 over the next three months. The case for its drug avexitide is real, but the market already knows the main facts: the positive Phase 3 result and the funding. The full trial presentation on 15 November 2026 and a filing with the US Food and Drug Administration (FDA) by year-end 2026 settle whether anything new is left to price.
The rating is Low because the main positives are already public. LUCIDITY, the Phase 3 trial, read out on 18 August 2026 with a 55% reduction in serious hypoglycemic events versus placebo. The 5 November 2026 third-quarter report showed $768.1 million of cash and kept the plan to submit the New Drug Application (NDA) by the end of 2026 (company 8-K exhibit, 5 November 2026). Nothing new arrives until the ObesityWeek presentation.
The price reflects a successful filing and a 2027 launch. The shares closed at $31.80 on 11 November 2026, up 41.5% over three months, and 22.7% below the $41.14 intraday 52-week high of 21 August 2026. They remain under the $35.50 price at which Amylyx sold 14,090,000 new shares on 19 August 2026.
Bullish and bearish views on Amylyx Pharmaceuticals, Inc.
The bull case on Amylyx Pharmaceuticals, Inc. (AMLX), in brief: the pivotal trial met every endpoint. The bear case: the shares trade below the offering price.
Bull case
- The pivotal trial met every endpoint. LUCIDITY randomized 78 adults and cut Level 2 and Level 3 hypoglycemic events by 55% versus placebo, meeting its primary and all secondary endpoints (Amylyx release, 18 August 2026). On the 5 November 2026 call, management said more than 90% of participants completed the 16-week double-blind period, and no serious adverse events were judged treatment-related (TipRanks call summary, 6 November 2026).
- No approved therapy exists for the condition. The drug treats post-bariatric hypoglycemia (PBH), dangerous low blood sugar after weight-loss surgery. PBH has no FDA-approved treatment. The company estimates about 160,000 US patients, and a PBH-specific diagnosis code took effect in October 2026 (Amylyx release, 4 November 2026; earnings call, 5 November 2026).
- Cash covers the launch. Cash and marketable securities were $768.1 million at 30 September 2026, against a third-quarter net loss of $45.5 million, or $0.38 per share (company 8-K exhibit, 5 November 2026). Management pointed to a potential 2027 launch on the 5 November 2026 call.
- Regulatory designations support a quick review. Avexitide holds FDA Breakthrough Therapy Designation for PBH and congenital hyperinsulinism, plus Orphan Drug Designation (Amylyx release, 4 November 2026).
- Analysts' targets sit above the price. Mizuho raised its target to $39 from $38 and kept an Outperform rating (company news, 9 November 2026 and 10 November 2026). That target came after the third-quarter report.
Bear case
- The shares trade below the offering price. The $31.80 close on 11 November 2026 is under the $35.50 price paid in the 19 August 2026 offering. Buyers in that offering hold a loss, and some may sell into any rise toward $35.50.
- Insiders sold after the data. On 10 September 2026, co-CEOs Justin Klee and Joshua Cohen each sold 30,464 shares at average prices of $32.18 and $32.19. The Chief Financial Officer, Chief Medical Officer and Chief Legal Officer also sold that day. Director George Milne sold 30,000 shares at $27.70 on 5 October 2026 under a Rule 10b5-1 trading plan (SEC Form 4 filings).
- One drug carries the valuation. Amylyx has had no product revenue since RELYVRIO/ALBRIOZA was withdrawn in April 2024. The ALS drug AMX0114 is still in an early dose-finding study, and AMX0318 targets an Investigational New Drug filing in 2027 (earnings call, 5 November 2026).
- Spending is climbing before any revenue. Third-quarter operating expenses were $49.7 million, up 38% year over year. Research and development rose to $28.4 million from $19.9 million, and selling, general and administrative expense rose to $21.3 million from $16.2 million (company 8-K exhibit, 5 November 2026).
- The trial was small and short. LUCIDITY enrolled 78 patients at 21 US sites over 16 weeks, and the year-end filing date is a company target rather than a scheduled event. Pricing, label and payer talks are still open; management said payer discussions begin in the first quarter of 2027 (earnings call, 5 November 2026).
Price setup
The shares closed at $31.80 on 11 November 2026, above the 50-day moving average of $29.81 and well above the 200-day moving average of $20.64. The close on the 5 November 2026 report day was $27.62, down from $29.40 on 4 November 2026. Four straight higher closes followed, ending at $31.80.
Above the price, the case turns on two levels. The first is the $35.50 offering price from 19 August 2026. The second is the $41.14 intraday 52-week high from 21 August 2026, set in the days after the topline data. Below the price, the 52-week closing low was $11.38 on 6 January 2026, before the trial read out.
The rise into the 15 November 2026 presentation means some of the event is already priced. The September insider sales came at prices of $32 to $33, close to the 11 November 2026 close.
Catalysts ahead
- 15 November 2026: Full LUCIDITY results as a late-breaking oral at ObesityWeek 2026, Washington, D.C. (8:30 a.m. ET), followed by an Amylyx investor event at 11:45 a.m. ET. Durability, dropout and safety detail shows whether the 55% topline reduction holds and what FDA reviewers will see; results already reflected in the price would leave little left to drive the shares.
- ~31 December 2026 (est.): Company-guided deadline for submitting the avexitide NDA to the FDA. An announced submission completes the regulatory half of the case; the year ending without one breaks it. It is a guidance deadline, not a scheduled filing date.
What would change the view
A daily close above $39.66, the August 2026 closing peak after the topline data, would show the shares leading the S&P 500 and prove this call wrong.
What it trades with
Avexitide is a glucagon-like peptide-1 (GLP-1) receptor antagonist. It works the opposite way to semaglutide and tirzepatide, which activate that receptor. Headlines about those weight-loss drugs therefore say little about Amylyx. The shares move on company news, the offering price and the mood in small-cap biotech. Avexitide's patients come mostly from gastric bypass and sleeve gastrectomy, so bariatric surgery volumes matter more to the market size than GLP-1 sales do.
The evidence, claim by claim (8)
- Cash, cash equivalents and marketable securities were $768.1 million at 30 September 2026, up from $250.8 million at 30 June 2026, including about $544.6 million of net offering proceeds. Amylyx Q3 2026 results release (8-K exhibit 99.1) · as of
- Third-quarter net loss was $45.5 million ($0.38 per share). R&D expense was $28.4 million versus $19.9 million a year earlier; SG&A was $21.3 million versus $16.2 million. Amylyx Q3 2026 results release (8-K exhibit 99.1) · as of
- Amylyx said it remains on track to submit the avexitide NDA by the end of 2026, and management pointed to a potential 2027 launch. Amylyx Q3 2026 results release and 5 November 2026 earnings call · as of
- LUCIDITY Phase 3 (78 adults) showed a 55% reduction in Level 2 and Level 3 hypoglycemic events versus placebo; over 90% completed the 16-week period, with no treatment-related serious adverse events. Amylyx topline release 18 August 2026; 5 November 2026 earnings call · as of
- Upsized public offering of 14,090,000 shares priced at $35.50 per share. Amylyx pricing press release and Form 8-K · as of
- Co-CEOs Justin Klee and Joshua Cohen each sold 30,464 shares at averages of $32.18 and $32.19; the CFO, CMO and CLO also sold shares the same day. SEC Form 4 filings dated 14 September 2026 · as of
- Director George M. Milne Jr. sold 30,000 shares at $27.70 under a Rule 10b5-1 plan. SEC Form 4 filed 7 October 2026 · as of
- Mizuho raised its Amylyx price target to $39 from $38 and maintained an Outperform rating. Mizuho analyst action, company news headline · as of
Sources
- Amylyx Pharmaceuticals, Inc. - Form 8-K - FY2026 (2026-11-05) · sec.gov ·
- Amylyx Earnings Call Highlights Avexitide's 2027 Launch Path · tipranks.com ·
- Amylyx sets Nov. 15 investor event on trial results · stocktitan.net ·
- Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting · amylyx.com
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
ABCL
AbCellera Biologics
AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its…
IBRX
ImmunityBio
ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…